Cargando…
Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience
INTRODUCTION: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH). Tadalafil is a PDE5 inhibitor with a long half life (16 h), stable pharmacokinetics and pharmacodynamics, and minim...
Autores principales: | Youssef, David Edward, Handler, Stephanie S., Richards, Susan Marjorie, Sheppard, Catherine Anne, Smith, Jenna, Tillman, Kathryn, Pietrosanu, Matthew, Kirkpatrick, Edward, Bates, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909267/ https://www.ncbi.nlm.nih.gov/pubmed/36776903 http://dx.doi.org/10.3389/fped.2023.1055131 |
Ejemplares similares
-
A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients
por: Youssef, David Edward, et al.
Publicado: (2023) -
A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients
por: Youssef, David, et al.
Publicado: (2023) -
Pulmonary Vein Stenosis: Moving From Past Pessimism to Future Optimism
por: McLennan, Daniel I., et al.
Publicado: (2021) -
Editorial: Advances in the care of the pediatric pulmonary hypertension patient: from the neonate to the adolescent-young adult patient
por: Avitabile, Catherine M., et al.
Publicado: (2023) -
Assessment of quality of life in pediatric patients with pulmonary
hypertension
por: Handler, Stephanie S., et al.
Publicado: (2018)